PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia

Published:2012-11-19 Issue:5 Volume:27 Page:1090-1099
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Spaner D E,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2012329.pdf

Reference36 articles.

1. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012, e-pub ahead of print 22 October 2012.

2. Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S . Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101–4107.

3. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.

4. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, Krauss RM . VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res 2010; 51: 2275–2281.

5. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11–20.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. m6A‐Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia;Advanced Science;2023-10-11

2. The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis;Metabolites;2023-06-27

3. Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia;PPAR Research;2023-06-26

4. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma;International Journal of Molecular Sciences;2023-03-13

5. Therapeutic inhibition of PPARα-HIF1α-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia;Cancer Letters;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3